Publications

These are original research publications using samples obtained from the NIAID COVID Consortium. Each paper addresses one or more of the scientific questions outlined in the project pages, with the goal of elucidating the immune response to COVID-19.

Publications

  1. Delmonte, O., Oguz, C., Dobbs, K., et al. Perturbations of the T-cell receptor repertoire in response to SARS-CoV-2 in immunocompetent and immunocompromised individuals. J Allergy Clin Immunol. 2024 Jun;153(6):1655-1667. doi: 10.1016/j.jaci.2023.12.011.
  2. Le Voyer, T., Parent, A. V., Liu, X., et al. Autoantibodies against type I IFNs in humans with alternative NF-κB pathway deficiency. Nature. 2023 Nov;623(7988):803-813. doi: 10.1038/s41586-023-06717-x. 
  3. Bastard, P., Vazquez, S., Liu, J., et al. Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. Sci Immunol. 2023 Dec 22;8(90):eabp8966. doi: 10.1126/sciimmunol.abp8966.
  4. Matuozzo, D., Talouarn, E., Marchal, A., et al. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19. Genome Med. 2023 Apr 5;15(1):22. doi: 10.1186/s13073-023-01173-8.
  5. Redmond, C., Kitakule, M., Son, A., et al. Deep immune profiling uncovers novel associations with clinical phenotypes of multisystem inflammatory syndrome in children (MIS-C). Ann Rheum Dis. 2023 Mar;82(3):442-445. doi: 10.1136/ard-2022-223269.
  6. Ford, M., Hari, A., Rodriguez, O., et al. ImmunoTyper-SR: A computational approach for genotyping immunoglobulin heavy chain variable genes using short-read data. Cell Syst. 2022 Oct 19;13(10):808-816.e5. doi: 10.1016/j.cels.2022.08.008.
  7. Zhou, Y., Shalhoub, R., Rogers, S., et al. Clonal hematopoiesis is not significantly associated with COVID-19 disease severity. Blood. 2022 Oct 6;140(14):1650-1655. doi: 10.1182/blood.2022015721.
  8. Wang, L., Candia, J., Ma, L., et al. Serological responses to human virome define clinical outcomes of Italian patients infected with SARS-CoV-2. Int J Biol Sci. 2022 Sep 1;18(15):5591-5606. doi: 10.7150/ijbs.78002.
  9. Shaw, E., Rosen, L., Cheng, A., et al. Temporal Dynamics of Anti-Type 1 Interferon Autoantibodies in Patients With Coronavirus Disease 2019. Clin Infect Dis. 2022 Aug 24;75(1):e1192-e1194. doi: 10.1093/cid/ciab1002.
  10. Carmona-Rivera, C., Zhang, Y., Dobbs, K., et al. Multicenter analysis of neutrophil extracellular trap dysregulation in adult and pediatric COVID-19. JCI Insight. 2022 Aug 22;7(16):e160332. doi: 10.1172/jci.insight.160332.
  11. Manry, J., Bastard, P., Gervais, A., et al. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proc Natl Acad Sci U S A. 2022 May 24; 119(21): e2200413119. doi: 10.1073/pnas.2200413119
  12. Sacco, K., Castagnoli, R., Vakkilainen, S., et al. Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19. Nat Med. 2022 May;28(5):1050-1062. doi: 10.1038/s41591-022-01724-3.
  13. Masvekar, R., Kosa, P., Jin, K., et al. Prognostic value of serum/plasma neurofilament light chain for COVID-19-associated mortality. Ann Clin Transl Neurol. 2022 May;9(5):622-632. doi: 10.1002/acn3.51542.
  14. Burbelo, P., Castagnoli, R., Shimizu, C., et al. Autoantibodies Against Proteins Previously Associated With Autoimmunity in Adult and Pediatric Patients With COVID-19 and Children With MIS-C. Front Immunol. 2022 Mar 11:13:841126. doi: 10.3389/fimmu.2022.841126.
  15. Delmonte, O., Bergerson, J., Burbelo, P., et al. Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity. J Allergy Clin Immunol. 2021 Nov;148(5):1192-1197. doi: 10.1016/j.jaci.2021.08.016.
  16. Cattaneo, C., Cancelli, V., Imberti, L., et al. Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab. Blood Cancer J. 2021 Sep 14;11(9):151. doi: 10.1038/s41408-021-00546-9.
  17. Asano, T., Boisson, B., Onodi, F., et al. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Sci Immunol. 2021 Aug 19;6(62):eabl4348. doi: 10.1126/sciimmunol.abl4348.
  18. Bastard, P., Gervais, A., Le Voyer, T., et al. Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years old and account for ~ 20% of COVID-19 deaths. Sci Immunol. 2021 Aug 19;6(62):eabl4340. doi: 10.1126/sciimmunol.abl4340.
  19. Zhang, Q., Cobat, A., Bastard, P., et al. Association of rare predicted loss-of-function variants of influenza-related type I IFN genes with critical COVID-19 pneumonia. J Clin Invest. 2021 Aug 2;131(15):e152474. doi: 10.1172/JCI152474.
  20. Abers, M., Rosen, L., Delmonte, O., et al. Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19. Immunol Cell Biol. 2021 Jul 26. doi: 10.1111/imcb.12495.
  21. Bastard, P., Orlova, E., Sozaeva, L., et al. Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. J Exp Med. 2021 Jul 5;218(7):e20210554. doi: 10.1084/jem.20210554.
  22. Liu, C., Martins, M., Lau, W., et al. Time-resolved Systems Immunology Reveals a Late Juncture Linked to Fatal COVID-19. Cell. 2021 Apr 1;184(7):1836-1857.e22. doi: 10.1016/j.cell.2021.02.018.
  23. Novelli, G., Liu, J., Biancolella, M., et al. Inhibition of HECT E3 ligases as potential therapy for COVID-19. Cell Death Dis. 2021 Mar 24;12(4):310. doi: 10.1038/s41419-021-03513-1.
  24. Abers, M., Delmonte, O., Ricotta, E., et al. An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight. 2021 Jan 11;6(1):e144455. doi: 10.1172/jci.insight.144455.
  25. Bastard, P., Rosen, L., Zhang, Q., et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020 Oct 23;370(6515):eabd4585. doi: 10.1126/science.abd4585.
  26. Zhang, Q., Bastard, P., Liu, Z., et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020 Oct 23;370(6515):eabd4570. doi: 10.1126/science.abd4570.

Preprints

  1. Matuozzo, D., Talouarn, E., Marchal, A., et al. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19. medRxiv. 2022 Oct 25:2022.10.22.22281221. doi: 10.1101/2022.10.22.22281221.
  2. Redmond, C., Kitakule M., Son, A., et al. Deep immune profiling uncovers novel associations with clinical phenotypes of Multisystem Inflammatory Syndrome in Children (MIS-C). medRxiv. 2022 Sep 2:2022.08.31.22279265. doi: 10.1101/2022.08.31.22279265.
  3. Carmona-Rivera, C., Zhang, Y., Dobbs, K. et al. Multicenter analysis of neutrophil extracellular trap dysregulation in adult and pediatric COVID-19. medRxiv. 2022 Mar 3:2022.02.24.22271475. doi: 10.1101/2022.02.24.22271475.
  4. Ford, M., Hari, A., Rodriguez, O., et al. ImmunoTyper-SR: A Novel Computational Approach for Genotyping Immunoglobulin Heavy Chain Variable Genes using Short Read Data. bioRxiv. 2022 Feb 2:2022.01.31.478564. doi: 10.1101/2022.01.31.478564.
  5. Masvekar, R., Kosa, P., Jin, K., et al. Prognostic Value of Serum/Plasma Neurofilament Light Chain for COVID-19 Associated Mortality. medRxiv. 2022 Jan 14:2022.01.13.22269244. doi: 10.1101/2022.01.13.22269244.
  6. Snyder, T., Gittelman, R., Klinger, M., et al. Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels. medRxiv. 2020 Sep 17;2020.07.31.20165647. doi: 10.1101/2020.07.31.20165647.
  7. Wang L, Candia J, Ma L, et al. Serological Responses to Human Virome Define Clinical Outcomes of Italian Patients Infected with SARS-CoV-2. medRxiv. 2020 Sep 7:2020.09.04.20187088. doi: 10.1101/2020.09.04.20187088.
  8. Nolan, S., Vignali, M., Klinger, M., et al. A large-scale database of T-cell receptor beta (TCRβ) sequences and binding associations from natural and synthetic exposure to SARS-CoV-2. Res Sq. 2020 Aug 4:rs.3.rs-51964. doi: 10.21203/rs.3.rs-51964/v1.

Reviews, Editorials, & Commentaries on SARS-CoV-2

  1. Su, H., Jing, H., Zhang, Y., et al. Interfering with interferons; a critical mechanism for critical COVID-19 pneumonia. Ann Rev Immunol. 2023 Apr 26;41:561-585. doi: 10.1146/annurev-immunol-101921-050835
  2. Delmonte, O., Catagnoli, R., Notarangelo, L. COVID-19 and Inborn Errors of Immunity. Physiology (Bethesda). 2022 Nov 1;37(6):0. doi: 10.1152/physiol.00016.2022.
  3. Stack, M., Sacco, K., Castagnoli, R., et al. BTK inhibitors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A systematic review. Clin Immunol. 2021 Sep;230:108816. doi: 10.1016/j.clim.2021.108816. 
  4. Vinh, D., Abel, L., Bastard, P., et al. Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-β. J Clin Immunol. 2021 Jun 8:1-18. doi: 10.1007/s10875-021-01068-6.
  5. Sancho-Shimizu V, Brodin P, Cobat A, et al. SARS-CoV-2-related MIS-C: A key to the viral and genetic causes of Kawasaki disease? J Exp Med. 2021 Jun 7;218(6):e20210446. doi: 10.1084/jem.20210446.
  6. Zhang, Q., Bastard, P., Bolze, A., et al. Life-Threatening COVID-19: Defective Interferons Unleash Excessive Inflammation. Med (N Y). 2020 Dec 18;1(1):14-20. doi: 10.1016/j.medj.2020.12.001.
  7. Zhang, S., Zhang, Q., Casanova, J., et al. Severe COVID-19 in the young and healthy: monogenic inborn errors of immunity? Nat Rev Immunol. 2020 Aug;20(8):455-456. doi: 10.1038/s41577-020-0373-7.
  8. Casanova, J., and Su, H. A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection. Cell. 2020 Jun 11;181(6):1194-1199. doi: 10.1016/j.cell.2020.05.016.
Content last reviewed on